XML 21 R12.htm IDEA: XBRL DOCUMENT
v3.22.2

Revenue from collaboration agreements | 6 Months Ended
--- | ---
Jun. 30, 2022
Text Block [Abstract] |
Revenue from collaboration agreements | 6. Revenue from collaboration agreements The Group earns revenue through strategic collaboration agreements with third party pharmaceutical and biotechnology companies. As of June 30, 2022, the Group had five strategic collaboration agreements in place. During the six months ended June 30, 2022, the Group entered into new collaboration agreements with BMS. Refer to Note 2 “License, Development and Commercialization agreement with BMS”, “License, Development and Commercialization agreement with Bristol-Myers-Squibb to develop Gamma Delta Allogeneic Cell Therapy program” and “Amendment to Strategic Collaboration Agreement with Bristol-Myers-Squibb on novel adoptive cell therapies” for further details. Four of the five collaboration agreements are still at pre-clinical stage and the BMS IMA401 collaboration agreement is at clinical stage. As the Amgen collaboration agreement was terminated in October 2021, the Group did not recognize any revenue for this collaboration for the three and six months ended June 30, 2022. The Group earned revenue from collaboration agreements from the following collaborators during the three and six months ended June 30, 2022 and 2021:
|  | Three months ended June 30, |  |  | Six months ended June 30, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
| (Euros in thousands) |  |  | (Euros in thousands) |
Amgen |  |  | — |  |  |  | 260 |  |  |  | — |  |  |  | 517 |
Genmab |  |  | 4,125 |  |  |  | 2,105 |  |  |  | 7,044 |  |  |  | 4,341 |
BMS |  |  | 12,107 |  |  |  | 1,297 |  |  |  | 110,532 |  |  |  | 4,590 |
GSK |  |  | 983 |  |  |  | 1,527 |  |  |  | 2,547 |  |  |  | 3,144 |
Total |  |  | 17,215 |  |  |  | 5,189 |  |  |  | 120,123 |  |  |  | 12,592 |
The revenue from collaboration agreements with BMS includes the revenue regarding the right-to-use license for IMA401 amounting to €91.3 million for the six months ended June 30, 2022. The Group recognized €19.2 million revenue based on the cost-to-cost method regarding the four collaboration agreements with BMS for the six months ended June 30, 2022. As of June 30, 2022, the Group has not recognized any milestone revenue under the collaboration agreements, due to the scientific uncertainty of achieving the milestones or the successful commercialization of a product. As of June 30, 2022, Immatics had not received any milestone or royalty payments in connection with the collaboration agreements. The Group expects to recognize the remaining deferred revenue balance into revenue as it performs the related performance obligations under each contract. Deferred revenue related to the collaboration agreements consists of the following as of June 30, 2022 and December 31, 2021:
|  | As of |
|  | June 30, 2022 |  |  | December 31, 2021 |
|  | (Euros in thousands) |
Current |  |  | 78,394 |  |  |  | 50,402 |
Non-current |  |  | 115,321 |  |  |  | 48,225 |
Total |  |  | 193,715 |  |  |  | 98,627 |
The Group recognized expenses related to the amortization of capitalized cost of obtaining a contract of €0.2 million and €0.1 million for the three months ended June 30, 2022 and June 30, 2021. The Group recognized expenses related to the amortization of capitalized cost of obtaining a contract of €0.3 million and €0.1 million for the six months ended June 30, 2022 and June 30, 2021.

X
- Definition The entire disclosure for revenue from contracts with customers. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Section Presentation -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2021-01-01 -Section Disclosure -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text block. + References No definition available. + Details
Name: | imtx_TextBlockAbstract
Namespace Prefix: | imtx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration